Drug
Eslicarbazepine acetate (BIA 2-093)
Eslicarbazepine acetate (BIA 2-093) is a pharmaceutical drug with 5 clinical trials. Historical success rate of 60.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
60.0%
Based on 3 completed trials
Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_2
1
20%
Ph phase_3
4
80%
Phase Distribution
0
Early Stage
1
Mid Stage
4
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
4(80.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (20.0%)
Phase 34 (80.0%)
Trials by Status
completed360%
terminated240%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_3
Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
NCT00988156
completedphase_3
Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures
NCT01162460
completedphase_2
Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
NCT01527513
terminatedphase_3
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
NCT01129960
terminatedphase_3
Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia
NCT01124097
Clinical Trials (5)
Showing 5 of 5 trials
NCT00988156Phase 3
Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
NCT01162460Phase 3
Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures
NCT01527513Phase 2
Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
NCT01129960Phase 3
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
NCT01124097Phase 3
Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5